HIGHLIGHTS
- who: Yangfu Jiang from the (UNIVERSITY) have published the article: Exploiting RIG-I-like receptor pathway for cancer immunotherapy, in the Journal: (JOURNAL)
- what: The authors describe how RLRs can be activated by synthetic viruses and radio-chemotherapy and how the agonists of RLRs can be systemically delivered in vivo.
SUMMARY
Mechanistically, sustained inflammation or immune_response during host-pathogen interaction increases cancer risk by promoting mutagenesis, genome instability, epigenetic changes and cytokine response. Activation of RLRs leads to the transcriptional induction of type I/III interferons and other cytokines that reinforce . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.